Estudo randomizado | Tratamento antirretroviral de baixo custo e de fácil adesão, baseado em dolutegravir, como terapia de primeira ou segunda linha foi não inferior ao tratamento padrão da infecção por HIV-1 em crianças.

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Easy-to-take medicine better at suppressing HIV in children – University College London

Comentários no Twitter

Dolutegravir-based antiretroviral therapy was compared with standard care in children and adolescents starting first- or second-line therapy for HIV type 1 infection. Dolutegravir-based ART was superior to standard-care ART. https://t.co/PP0XaEVswO pic.twitter.com/pQvhjdXcUk

— NEJM (@NEJM) December 29, 2021

Visual Abstract: Dolutegravir as First- or Second-Line HIV Treatment in Children https://t.co/2RIg9uH2V1 pic.twitter.com/mDr1Z6l6CJ

— NEJM (@NEJM) January 4, 2022